The upcoming Raptor brain disorder drug didn’t show any statistical significant in its trials, but the new drug is expected to get significant development before its registration study. The drug, out of Raptor Pharmaceutical Corp, is under development for patients with Huntington’s Disease.
Raptor Brain Disorder Drug Hopes to Be the First to Slow Huntington’s Disease Progression
Huntington’s Disease is a type of neurodegenerative disorder that affects muscle coordination. It can lead to mental decline and give several symptoms related to behavior, and it is genetic. The Raptor brain disorder drug is the first to show a slowing rate in motor score when it was tested opposite a placebo in a 36-month study.
The drug, called RP103, is reported to be clinically meaningful by Raptor, as there is no other drug that has been proven to slow the development of Huntington’s Disease. Even if the effectiveness was rated at 25%, it’s a step in the right direction.
2015 Has Been A Bad Year for Raptor
The pharmaceutical company’s stocks have seen a dramatic drop in 2015. As of Wednesday, the share price is at $5.60, having fallen 47% throughout the year. With this drug, it is surely hoping to see an increase. If RP103 is fully developed and shows effectiveness, it could put Raptor back on the map.
Total motor score is the scale through which the progression of Huntington’s Disease is measured, and even if the progression is small, it is still of significance. Further research and more investments can bring both the company and patients suffering from this cruel disease some good news. The lack of faith in the company probably stems from the fact that it stopped developing a liver drug earlier in the year after it couldn’t prove as significant during trials. Since it hasn’t given up on RP103, it’s possible that this one may work.
